These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 29119292)

  • 1. Population pharmacokinetics of nintedanib, an inhibitor of tyrosine kinases, in patients with non-small cell lung cancer or idiopathic pulmonary fibrosis.
    Schmid U; Liesenfeld KH; Fleury A; Dallinger C; Freiwald M
    Cancer Chemother Pharmacol; 2018 Jan; 81(1):89-101. PubMed ID: 29119292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of nintedanib in patients with idiopathic pulmonary fibrosis.
    Schmid U; Doege C; Dallinger C; Freiwald M
    Pulm Pharmacol Ther; 2018 Feb; 48():136-143. PubMed ID: 29133080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib.
    Wind S; Schmid U; Freiwald M; Marzin K; Lotz R; Ebner T; Stopfer P; Dallinger C
    Clin Pharmacokinet; 2019 Sep; 58(9):1131-1147. PubMed ID: 31016670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic Properties of Nintedanib in Healthy Volunteers and Patients With Advanced Cancer.
    Dallinger C; Trommeshauser D; Marzin K; Liesener A; Kaiser R; Stopfer P
    J Clin Pharmacol; 2016 Nov; 56(11):1387-1394. PubMed ID: 27093880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exposure-efficacy analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.
    Schmid U; Weber B; Magnusson MO; Freiwald M
    Respir Med; 2021; 180():106369. PubMed ID: 33798871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of afatinib, an irreversible ErbB family blocker, in patients with various solid tumors.
    Freiwald M; Schmid U; Fleury A; Wind S; Stopfer P; Staab A
    Cancer Chemother Pharmacol; 2014 Apr; 73(4):759-70. PubMed ID: 24522402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nintedanib: first global approval.
    McCormack PL
    Drugs; 2015 Jan; 75(1):129-39. PubMed ID: 25430078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nintedanib: a novel therapeutic approach for idiopathic pulmonary fibrosis.
    Dimitroulis IA
    Respir Care; 2014 Sep; 59(9):1450-5. PubMed ID: 24782550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of nintedanib on non-small cell lung cancer in a patient with idiopathic pulmonary fibrosis: A case report and literature review.
    Shiratori T; Tanaka H; Tabe C; Tsuchiya J; Ishioka Y; Itoga M; Taima K; Takanashi S; Tasaka S
    Thorac Cancer; 2020 Jun; 11(6):1720-1723. PubMed ID: 32285615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nintedanib allows retreatment with atezolizumab of combined non-small cell lung cancer/idiopathic pulmonary fibrosis after atezolizumab-induced pneumonitis: a case report.
    Yamakawa H; Oba T; Ohta H; Tsukahara Y; Kida G; Tsumiyama E; Nishizawa T; Kawabe R; Sato S; Akasaka K; Amano M; Kuwano K; Matsushima H
    BMC Pulm Med; 2019 Aug; 19(1):156. PubMed ID: 31438923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design of the INPULSIS™ trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis.
    Richeldi L; Cottin V; Flaherty KR; Kolb M; Inoue Y; Raghu G; Taniguchi H; Hansell DM; Nicholson AG; Le Maulf F; Stowasser S; Collard HR
    Respir Med; 2014 Jul; 108(7):1023-30. PubMed ID: 24834811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exposure-safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.
    Schmid U; Weber B; Sarr C; Freiwald M
    BMC Pulm Med; 2021 Jul; 21(1):244. PubMed ID: 34289823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetic analysis of patritumab, a HER3 inhibitor, in subjects with advanced non-small cell lung cancer (NSCLC) or solid tumors.
    Yoshiba S; Jansen M; Matsushima N; Chen S; Mendell J
    Cancer Chemother Pharmacol; 2016 May; 77(5):987-96. PubMed ID: 27017616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of Nintedanib in Subjects With Hepatic Impairment.
    Marzin K; Kretschmar G; Luedtke D; Kraemer S; Kuelzer R; Schlenker-Herceg R; Schmid U; Schnell D; Dallinger C
    J Clin Pharmacol; 2018 Mar; 58(3):357-363. PubMed ID: 29106740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nintedanib: A Review of Its Use in Patients with Idiopathic Pulmonary Fibrosis.
    Keating GM
    Drugs; 2015 Jul; 75(10):1131-40. PubMed ID: 26063212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib.
    Bonella F; Stowasser S; Wollin L
    Drug Des Devel Ther; 2015; 9():6407-19. PubMed ID: 26715838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population Pharmacokinetics of Erlotinib in Patients With Non-small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older Patients.
    Evelina Cardoso ; Guidi M; Khoudour N; Pascaline Boudou-Rouquette ; Fabre E; Tlemsani C; Arrondeau J; François Goldwasser ; Vidal M; Schneider MP; Wagner AD; Widmer N; Blanchet B; Csajka C
    Clin Ther; 2020 Jul; 42(7):1302-1316. PubMed ID: 32631634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nintedanib for the treatment of idiopathic pulmonary fibrosis.
    Varone F; Sgalla G; Iovene B; Bruni T; Richeldi L
    Expert Opin Pharmacother; 2018 Feb; 19(2):167-175. PubMed ID: 29327616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nintedanib in idiopathic pulmonary fibrosis.
    Woodcock HV; Maher TM
    Drugs Today (Barc); 2015 Jun; 51(6):345-56. PubMed ID: 26261848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib.
    Woodcock HV; Molyneaux PL; Maher TM
    Drug Des Devel Ther; 2013; 7():503-10. PubMed ID: 23818761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.